The Great Masquerader: Tuberculosis Presenting as Community-Acquired Pneumonia

Keertan Dheda; Edson Makambwa; Aliasgar Esmail

doi:10.1055/s-0040-1710583

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2020; 41(04): 592-604
DOI: 10.1055/s-0040-1710583

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Great Masquerader: Tuberculosis Presenting as Community-Acquired Pneumonia

Keertan Dheda

¹Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa

²Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

,

Edson Makambwa

¹Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa

,

Aliasgar Esmail

¹Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa

› Institutsangaben

Abstract

According to World Health Organization estimates, tuberculosis (TB) and lower respiratory tract infections (LRTIs) are both among the top 10 global causes of death. TB and community-acquired pneumonia (CAP), if mortality estimates are combined, would rank as the third most common cause of death globally. It is estimated that each year there are approximately 10 million new cases of TB that are associated with approximately 1.2 million deaths, and almost 450 million new episodes of LRTI (synonymous with CAP) with approximately 4 million associated deaths. Globally, Streptococcus pneumoniae remains the most common cause of CAP. However, although well documented, it is not widely appreciated that in several parts of the world, including sub-Saharan Africa, Asia, and South America, Mycobacterium tuberculosis is an important cause of CAP, if not the most common organism isolated in such settings. Thus, CAP due to M. tuberculosis is not uncommon in some parts of the world with up to a third of cases being attributable to M. tuberculosis. Consequently, TB remains an important clinical entity in the intensive care unit in these settings. Despite its frequency and importance, there are very limited data about TB CAP. In this review we discussed the epidemiology, immunopathogenesis, clinical presentation, diagnosis, management, prognosis, and prevention of TB CAP. The utility of newer diagnostic approaches is highlighted.

Keywords

tuberculosis - community-acquired pneumonia - lower respiratory tract infection - intensive care unit - critically ill

Volltext

Referenzen

References
1 Dheda K, Barry III CE, Maartens G. Tuberculosis. Lancet 2016; 387 (10024): 1211-1226
2 Global tuberculosis report 2019. Available at: https://www.who.int/tb/publications/global_report/en/ . Accessed April 7, 2020
3 Liam CK, Pang YK, Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006; 11 (06) 786-792
4 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385 (9963): 117-171
5 Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009; 4 (05) e5561
6 Olayanju O, Esmail A, Limberis J, Gina P, Dheda K. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. Int J Infect Dis 2019; 85: 74-79
7 Schnippel K, Ndjeka N, Maartens G. , et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6 (09) 699-706
8 Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 2007; 8 (02) 124-133
9 Starke JR. Diagnosis of tuberculosis in children. Pediatr Infect Dis J 2000; 19 (11) 1095-1096
10 Cao B, Ren LL, Zhao F. , et al. Viral and mycoplasma pneumoniae community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China. Eur J Clin Microbiol Infect Dis 2010; 29 (11) 1443-1448
11 Grant AD, Sidibé K, Domoua K. , et al. Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire. Int J Tuberc Lung Dis 1998; 2 (11) 926-934
12 Walaza S, Tempia S, Dawood H. , et al. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. BMC Infect Dis 2015; 15: 26
13 Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007; 11 (12) 1308-1313
14 Gersh JK, Feldman Z, Greenberger E. , et al. Tuberculosis among individuals with community-acquired pneumonia presenting to emergency in Gaborone, Botswana. J Public Health Africa 2018; 9 (01) 803
15 Scott JA, Hall AJ, Muyodi C. , et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355 (9211): 1225-1230
16 Lui G, Ip M, Lee N. , et al. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia. Respirology 2009; 14 (08) 1098-1105
17 Lupisan S, Suzuki A, Macalalad N. , et al. Etiology and epidemiology of community-acquired pneumonia in adults requiring hospital admission: a prospective study in rural Central Philippines. Int J Infect Dis 2019; 80: 46-53
18 Vray M, Germani Y, Chan S. , et al. Clinical features and etiology of pneumonia in acid-fast bacillus sputum smear-negative HIV-infected patients hospitalized in Asia and Africa. AIDS 2008; 22 (11) 1323-1332
19 Naderi H, Sheybani F, Erfani SS, Amiri B, Nooghabi MJ. The mask of acute bacterial pneumonia may disguise the face of tuberculosis. Electron Physician 2017; 9 (03) 3943-3949
20 Oliwa JN, Karumbi JM, Marais BJ, Madhi SA, Graham SM. Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review. Lancet Respir Med 2015; 3 (03) 235-243
21 Peto L, Nadjm B, Horby P. , et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg 2014; 108 (06) 326-337
22 Hara K, Yahara K, Gotoh K. , et al. Clinical study concerning the relationship between community-acquired pneumonia and viral infection in northern Thailand. Intern Med 2011; 50 (09) 991-998
23 Calligaro GL, Zijenah LS, Peter JG. , et al. Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infect Dis 2017; 17 (04) 441-450
24 Claassens M, van Schalkwyk C, den Haan L. , et al. High prevalence of tuberculosis and insufficient case detection in two communities in the Western Cape, South Africa. PLoS One 2013; 8 (04) e58689
25 Middelkoop K, Mathema B, Myer L. , et al. Transmission of tuberculosis in a South African community with a high prevalence of HIV infection. J Infect Dis 2015; 211 (01) 53-61
26 Chan CH, Cohen M, Pang J. A prospective study of community-acquired pneumonia in Hong Kong. Chest 1992; 101 (02) 442-446
27 Moore DP, Klugman KP, Madhi SA. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J 2010; 29 (12) 1099-04
28 Schlossberg D. Acute tuberculosis. Infect Dis Clin North Am 2010; 24 (01) 139-146
29 Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15 (03) 433-450
30 Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis. Microbiol Spectr 2017; 5 (01) 5
31 Dheda K, Calligaro GL. Human immunodeficiency virus and tuberculosis co-infection. In: Davies P, Gordon S, Davies G. , eds. Clinical Tuberculosis. 5th ed. Boca Raton, Florida: CRC Press; 2014: 269-292
32 Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005; 192 (07) 1201-1209
33 Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, FitzGerald JM. ; Canadian Collaborative Group in nosocomial Transmission of Tuberculosis. Delay in diagnosis among hospitalized patients with active tuberculosis--predictors and outcomes. Am J Respir Crit Care Med 2002; 165 (07) 927-933
34 Cavallazzi R, Wiemken T, Christensen D. , et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. Eur Respir J 2014; 43 (01) 178-184
35 Chon SB, Kim TS, Oh WS, Lee SJ, Han SS, Kim WJ. Pulmonary tuberculosis among patients hospitalised with community-acquired pneumonia in a tuberculosis-prevalent area. Int J Tuberc Lung Dis 2013; 17 (12) 1626-1631
36 Shen GH, Tsao TC, Kao SJ. , et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012; 39 (03) 201-205
37 Kudjawu Y, Massari V, Sow O, Bah B, Larouzé B, Murray JF. Benefit of amoxicillin in differentiating between TB suspects whose initial AFB sputum smears are negative. Int J Tuberc Lung Dis 2006; 10 (04) 441-446
38 Calligaro GL, Theron G, Khalfey H. , et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med 2015; 3 (08) 621-630
39 Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin PT. Mortality among patients with tuberculosis requiring intensive care: a retrospective cohort study. BMC Infect Dis 2010; 10: 54
40 Sydow M, Schauer A, Crozier TA, Burchardi H. Multiple organ failure in generalized disseminated tuberculosis. Respir Med 1992; 86 (06) 517-519
41 Duro RP, Figueiredo Dias P, Ferreira AA. , et al. Severe tuberculosis requiring intensive care: a descriptive analysis. Crit Care Res Pract 2017; 2017: 9535463
42 Ferreira MD, Neves CPD, Souza AB. , et al. Predictors of mortality among intensive care unit patients coinfected with tuberculosis and HIV. J Bras Pneumol 2018; 44 (02) 118-124
43 Balkema CA, Irusen EM, Taljaard JJ, Koegelenberg CF. Tuberculosis in the intensive care unit: a prospective observational study. Int J Tuberc Lung Dis 2014; 18 (07) 824-830
44 Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-Ioanas M, Lode H. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006; 27 (06) 1223-1228
45 Lee PL, Jerng JS, Chang YL. , et al. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003; 22 (01) 141-147
46 Penner C, Roberts D, Kunimoto D, Manfreda J, Long R. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med 1995; 151 (3, Pt 1): 867-872
47 Zahar JR, Azoulay E, Klement E. , et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001; 27 (03) 513-520
48 Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121 (05) 1486-1492
49 Peter JG, Theron G, van Zyl-Smit R. , et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012; 40 (05) 1211-1220
50 Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369 (9578): 2042-2049
51 Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998; 76 (06) 651-662
52 Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4 (02) 97-107
53 Theron G, Peter J, Meldau R. , et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013; 68 (11) 1043-1051
54 Peter JG, Theron G, Singh N, Singh A, Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J 2014; 43 (01) 185-194
55 Peter JG, Theron G, Pooran A, Thomas J, Pascoe M, Dheda K. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Respir Med 2013; 1 (06) 471-478
56 Schleicher GK, Herbert V, Brink A. , et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25 (04) 688-692
57 Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10 (05) 510-515
58 Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med (Korean Assoc Intern Med) 2009; 24 (04) 337-342
59 Ugajin M, Miwa S, Shirai M. , et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011; 37 (02) 371-375
60 Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. Ann Lab Med 2013; 33 (02) 105-110
61 Richeldi L, Mariani M, Losi M. , et al. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 2004; 24 (02) 247-250
62 Global tuberculosis report 2018. Available at: https://www.who.int/tb/publications/global_report/en/ . Accessed April 7, 2020
63 Davis JL. Bringing patient-centered tuberculosis diagnosis into the light of day. BMC Med 2017; 15 (01) 219
64 Steingart KR, Henry M, Ng V. , et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6 (09) 570-581
65 van Zyl-Smit RN, Binder A, Meldau R. , et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 2011; 6 (12) e28815
66 Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 2004; 42 (05) 2321-2325
67 WHO consolidated guidelines on drug resistant tuberculosis treatment 2019. Available at: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/ . Accessed April 7, 2020
68 Chakravorty S, Simmons AM, Rowneki M. , et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care Testing. MBio 2017; 8 (04) 8
69 Pandie S, Peter JG, Kerbelker ZS. , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study. BMC Med 2014; 12: 101
70 Meldau R, Randall P, Pooran A. , et al. Same-day tools, including Xpert Ultra and IRISA-TB, for rapid diagnosis of pleural tuberculosis: a prospective observational study. J Clin Microbiol 2019; 57 (09) 57
71 Theron G, Venter R, Smith L. , et al. False-positive Xpert MTB/RIF results in retested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. J Clin Microbiol 2018; 56 (03) 56
72 Langley I, Lin HH, Egwaga S. , et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health 2014; 2 (10) e581-e591
73 Friedrich SO, Rachow A, Saathoff E. , et al; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1 (06) 462-470
74 Theron G, Zijenah L, Chanda D. , et al; TB-NEAT team. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383 (9915): 424-435
75 Cox HS, Mbhele S, Mohess N. , et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 2014; 11 (11) e1001760
76 Churchyard GJ, Stevens WS, Mametja LD. , et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3 (08) e450-e457
77 Theron G, Peter J, Richardson M. , et al. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014; (10) CD010705
78 Colman RE, Mace A, Seifert M. , et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med 2019; 16 (04) e1002794
79 Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex. 2018 . Available at: https://www.who.int/tb/publications/2018/WHO_technical_guide_nextgen_sequencing/en/ . Accessed April 7, 2020
80 Lawn SD, Dheda K, Kerkhoff AD. , et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013; 13: 407
81 O'Donnell MR, Jarand J, Loveday M. , et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010; 153 (08) 516-522
82 Adams S, Ehrlich R, Baatjies R. , et al. Incidence of occupational latent tuberculosis infection in South African healthcare workers. Eur Respir J 2015; 45 (05) 1364-1373
83 Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health 2008; 13 (05) 703-712
84 Mac Kenzie WR, Heilig CM, Bozeman L. , et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011; 6 (04) e18358
85 Weiner M, Peloquin C, Burman W. , et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54 (10) 4192-4200
86 Chigutsa E, Visser ME, Swart EC. , et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55 (09) 4122-4127
87 Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57 (01) 21-31
88 Saukkonen JJ, Cohn DL, Jasmer RM. , et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174 (08) 935-952
89 Huang J, Guo J, Li H, Huang W, Zhang T. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (13) e14636
90 Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016; 149 (01) 209-219
91 Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2016; 4: CD002244
92 Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (03) 223-237
93 Mayosi BM, Ntsekhe M, Bosch J. , et al; IMPI Trial Investigators. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014; 371 (12) 1121-1130
94 Otu A, Hashmi M, Mukhtar AM. , et al. The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. J Crit Care 2018; 45: 184-196
95 Torres A, Sibila O, Ferrer M. , et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
96 Peloquin CA, Nitta AT, Burman WJ. , et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30 (09) 919-925
97 Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62 (09) 727-735
98 McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50 (04) 1170-1177
99 Pillai G, Fourie PB, Padayatchi N. , et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (11) (Suppl. 03) S309-S316 , discussion S317–S321
100 Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62 (15) 2169-2183
101 Chideya S, Winston CA, Peloquin CA. , et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48 (12) 1685-1694
102 Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55 (02) 169-177
103 Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22 (02) 255-271 , vi
104 Koegelenberg CF, Nortje A, Lalla U. , et al. The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care. S Afr Med J 2013; 103 (06) 394-398
105 Crampin AC, Mwaungulu JN, Mwaungulu FD. , et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24 (03) 417-426
106 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. ; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (04) 251-261
107 Meintjes G, Wilkinson RJ, Morroni C. , et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24 (15) 2381-2390
108 Meintjes G, Stek C, Blumenthal L. , et al; PredART Trial Team. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med 2018; 379 (20) 1915-1925
109 Dheda K, Gumbo T, Gandhi NR. , et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2 (04) 321-338
110 Pietersen E, Ignatius E, Streicher EM. , et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383 (9924): 1230-1239
111 Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012; 379 (9817): 773-775
112 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67 (01) 71-79
113 Lin CH, Lin CJ, Kuo YW. , et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis 2014; 14: 5
114 Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration 2013; 86 (01) 76-85
115 Moodley L, Pillay J, Dheda K. Aspergilloma and the surgeon. J Thorac Dis 2014; 6 (03) 202-209
116 Van Der Meeren O, Hatherill M, Nduba V. , et al. Phase 2b controlled trial of M72/AS01_E vaccine to prevent tuberculosis. N Engl J Med 2018; 379 (17) 1621-1634
117 Roy A, Eisenhut M, Harris RJ. , et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014; 349: g4643
118 da Costa C, Walker B, Bonavia A. Tuberculosis vaccines--state of the art, and novel approaches to vaccine development. Int J Infect Dis 2015; 32: 5-12
119 Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol 2015; 98 (03) 347-356
120 Getahun H, Matteelli A, Abubakar I. , et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46 (06) 1563-1576
121 Churchyard GJ, Swindells S. Controlling latent TB tuberculosis infection in high-burden countries: a neglected strategy to end TB. PLoS Med 2019; 16 (04) e1002787
122 Latent TB. Infection: updated and consolidated guidelines for programmatic management. 2018 . Available at: https://www.who.int/tb/publications/latent-tuberculosis-infection/en/ . Accessed April 7, 2020
123 Broger T, Sossen B, du Toit E. , et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis 2019; 19 (08) 852-861
124 Prout S, Potgieter PD, Forder AA, Moodie JW, Matthews J. Acute community-acquired pneumonias. S Afr Med J 1983; 64 (12) 443-446
125 Song JH, Oh WS, Kang CI. , et al; Asian Network for Surveillance of Resistant Pathogens Study Group. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31 (02) 107-114
126 Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother 2004; 10 (06) 359-363
127 Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest 1998; 114 (06) 1588-1593
128 Loh LC, Khoo SK, Quah SY. , et al. Adult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admission. Respirology 2004; 9 (03) 379-386
129 Hooi LN, Looi I, Ng AJ. A study on community acquired pneumonia in adults requiring hospital admission in Penang. Med J Malaysia 2001; 56 (03) 275-284
130 Oberoi AAA. Bacteriological profile, serology and antibiotic sensitivity pattern of microorganisms from community acquired pneumonia. KJ Sci 2006; 8: 79-82
131 Lauderdale TL, Chang FY, Ben RJ. , et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005; 99 (09) 1079-1086
132 Yen MY, Hu BS, Chen YS. , et al. A prospective etiologic study of community-acquired pneumonia in Taiwan. J Formos Med Assoc 2005; 104 (10) 724-730
133 Hui KP, Chin NK, Chow K. , et al. Prospective study of the aetiology of adult community acquired bacterial pneumonia needing hospitalisation in Singapore. Singapore Med J 1993; 34 (04) 329-334